Valerie, a wellness company focused on supporting women through perimenopause, has announced the successful closure of a £514,000 pre-seed funding round. Notably, 45% of the funds raised came from female investors- more than triple the industry average, where only 14% of angel investors are women.
The round attracted backing from several prominent angel investors, among them Giles Brook, former CEO of Vita Coco and investor in health-focused brands including Surreal, Pip & Nut, and Freja.
The capital will go towards expanding its product line, which features a flagship supplement developed with patent-pending liposomal technology.
“We’re rethinking a category with unflinchingly real, big, bold energy and moments of mischief to build engaged community, coupled with a liquid supplement, Daily Essential, using patent-pending liposomal technology that’s genuinely changing women’s lives,” said Valerie Co-founder Olly Johnson in a LinkedIn post.
Valerie’s hero product, Daily Essential, leverages liposomal delivery to effectively target perimenopausal symptoms with key nutrients. The brand has already shown strong early performance, reporting an 84% rise in Q1 2025 sales compared to Q4 2024. It now forecasts reaching seven-figure revenue before the end of the year.
With search interest in perimenopause now outpacing menopause-related queries by a factor of four, Valerie is positioning itself at the forefront of a rapidly expanding sector.
The newly raised funding will be used to accelerate product development and fuel growth within the women’s health and wellness market.
